Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dorzolamide-Timolol as First Line Therapy for Glaucoma or Ocular Hypertension
NCT00546286Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2006
- Primary completion
- Aug 2007
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of dorzolamide, timolol in open-angle glaucoma (OAG), ocular hypertension, sponsored by Merck & Co.. Started May 2006; status: completed.
02
Drugs
dorzolamidetimolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT00546286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00546286.